Researchers find that dendritic cells transduced with Fas Ligand are effective in treating colon inflammation.
Dendritic cells are constantly sampling the lumen of the intestines for harmful bacterial. Once they find a threat, they migrate to the neighboring lymph nodes to activate T cells. Since our intestines contain hundreds of millions of bacterial cells, dendritic cells have developed to ignore the commensal bacteria that would not harm us. This “ignorance” or tolerance has proved essential for intestinal health. Breakdown of this tolerance results in inflammatory bowel diseases or IBD. We have previously written about how defective dendritic cells are to blame for the initiation of IBD.
IBD is a group of inflammatory diseases affecting the colon and can be divided into two main groups: Crohn’s disease and ulcerative colitis. Both types of disease share common pathological features, but overall there is a lot of heterogeneity because of genetic factors, environment, individual susceptibility and the immune system. In the US, IBD costs more than 2 billion dollars a year, and even with current treatments, there are still patients who do not respond well. Scientists are in constant search for new therapies.1
A recent study shows that transducing dendritic cells with Fas ligand made them better at modulating IBD severity. In this study, scientists transduced bone marrow dendritic cells from rats with Fas Ligand and then transferred them into rats before inducing IBD. Fas Ligand cells reduced the activation of T cells and increased T cell apoptosis. They also reduced the numbers of other inflammatory immune cells in the colon and decreased the damage in the colonic tissue, providing a novel way to regulate colon inflammation.2
At HemaCare, we are constantly following up on new regimens that can increase tolerance and help control IBD. We supply scientists with both dendritic cells and Crohn’s disease patient samples for their research needs. Give us a call us at (877) 397-3087 if you have any questions or would like to place an order.
2 Rivera de Jesus E. et al. 2016. Adoptive transfer of dendritic cells expressing Fas ligand modulates intestinal inflammation in a model of inflammatory bowel disease. J. Clin. Cell Immunol. 7(2) doi:10.4172/2155-9899.1000411.